Twice now management has stated:
SAN DIEGO, May 20, 2015 - should be sufficient to fund the company's drug discovery and development activities through June 30, 2016.
SAN DIEGO, July 23, 2015 - should be sufficient to fund the company's drug discovery and development activities at least through June 30, 2016."
That's a total of 5 future q's since the 3/31/15 filed numbers - or with .56 HARD CASH remaining - we can deduce a burn average of .11 per quarter for the next five quarters?
SAN DIEGO, July 23, 2015 - Lpath will actively explore partnering, licensing and monetization options for its pipeline assets...Lpath's relationship with Pfizer, its partner on the iSONEP wet AMD program, remains cooperative...
Does anyone know another biotech trading at 1/2 cash with multiple pipeline assets and a 'cooperative relationship with Pfizer'??? I would hit your stock, Twice!
